Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1Keratoacanthoma familial 1Dermoid Cyst 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × vactosertib × Clear all
NCT03724851 2025-03-25

Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer

MedPacto, Inc.

Phase 1/2 Completed
120 enrolled
Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT03698825 2024-12-09

TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer

MedPacto, Inc.

Phase 1/2 Completed
62 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡